JP7570929B2 - Ｌｉｆを定量化する方法及びその使用 - Google Patents

Ｌｉｆを定量化する方法及びその使用 Download PDF

Info

Publication number
JP7570929B2
JP7570929B2 JP2020570569A JP2020570569A JP7570929B2 JP 7570929 B2 JP7570929 B2 JP 7570929B2 JP 2020570569 A JP2020570569 A JP 2020570569A JP 2020570569 A JP2020570569 A JP 2020570569A JP 7570929 B2 JP7570929 B2 JP 7570929B2
Authority
JP
Japan
Prior art keywords
lif
amino acid
acid sequence
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020570569A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019243893A5 (https=
JP2021528411A (ja
JP2021528411A5 (https=
Inventor
ジョアン・セオアネ・スアレス
ジュディット・アニド・フォルゲイラ
パトリシア・アン・ギブリン
ピーター・エドワード・ベイリス
ヨハン・フランソン
アリフ・ジェタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
MedImmune Ltd
Original Assignee
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron, MedImmune Ltd filed Critical Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Publication of JP2021528411A publication Critical patent/JP2021528411A/ja
Publication of JPWO2019243893A5 publication Critical patent/JPWO2019243893A5/ja
Publication of JP2021528411A5 publication Critical patent/JP2021528411A5/ja
Application granted granted Critical
Publication of JP7570929B2 publication Critical patent/JP7570929B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5415—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5415—Leukaemia inhibitory factor [LIF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
JP2020570569A 2018-06-18 2019-06-17 Ｌｉｆを定量化する方法及びその使用 Active JP7570929B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382433.3 2018-06-18
EP18382433 2018-06-18
PCT/IB2019/000756 WO2019243893A1 (en) 2018-06-18 2019-06-17 Methods of quantifying lif and uses thereof

Publications (4)

Publication Number Publication Date
JP2021528411A JP2021528411A (ja) 2021-10-21
JPWO2019243893A5 JPWO2019243893A5 (https=) 2022-06-24
JP2021528411A5 JP2021528411A5 (https=) 2022-06-24
JP7570929B2 true JP7570929B2 (ja) 2024-10-22

Family

ID=62716028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570569A Active JP7570929B2 (ja) 2018-06-18 2019-06-17 Ｌｉｆを定量化する方法及びその使用

Country Status (5)

Country Link
US (1) US20210190798A1 (https=)
EP (1) EP3806960A1 (https=)
JP (1) JP7570929B2 (https=)
CN (1) CN112654395A (https=)
WO (1) WO2019243893A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020354255A1 (en) 2019-09-29 2022-04-21 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for LIF and use thereof
EP4069736A1 (en) * 2019-12-04 2022-10-12 MedImmune Limited Antibodies against lif and uses thereof
CN116298320B (zh) * 2023-03-31 2025-07-11 深圳迈瑞生物医疗电子股份有限公司 检测白血病抑制因子的试剂盒及检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057144A2 (en) * 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
WO2015040243A2 (en) * 2013-09-23 2015-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
K. Jin Kim et al.，Detection of human leukemia inhibitory factor by monoclonal antibody based ELISA，Journal of Immunological Methods,，1992年11月25日， Vol.156,No.1，PP.9-17

Also Published As

Publication number Publication date
EP3806960A1 (en) 2021-04-21
CN112654395A (zh) 2021-04-13
WO2019243893A1 (en) 2019-12-26
JP2021528411A (ja) 2021-10-21
US20210190798A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
US10206999B2 (en) Antibodies against LIF and uses thereof
US20230042095A1 (en) Antibodies against lif and uses thereof
AU2019269131B2 (en) Antibodies against LIF and dosage forms thereof
JP7570929B2 (ja) Ｌｉｆを定量化する方法及びその使用
JP7520727B2 (ja) 癌を有する個人における抗ｌｉｆ抗体治療に対する反応を向上させるための方法
JP7603772B2 (ja) 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
HK40051946A (en) Methods of quantifying lif and uses thereof
EA044934B1 (ru) Антитела к lif и лекарственные формы на их основе
EA051297B1 (ru) Антитела к lif и их применения
EA049383B1 (ru) Способы улучшения ответа на лечение с помощью антитела к lif у индивидуумов, страдающих от рака
EA045781B1 (ru) Антитела к lif и их применения
HK40040276B (zh) 抗lif抗体及其用途
HK40016422A (en) Antibodies against lif and uses thereof
HK40016422B (en) Antibodies against lif and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241009

R150 Certificate of patent or registration of utility model

Ref document number: 7570929

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150